following an abbreviated submission:
seladelpar (Livdelzi®) is accepted for use within NHSScotland.
Indication under review: for the treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
Seladelpar offers an additional treatment choice in the therapeutic class of peroxisome proliferator-activated receptor (PPAR) agonists.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice304KB (PDF)
Medicine details
- Medicine name:
- seladelpar (Livdelzi)
- SMC ID:
- SMC2946
- Indication:
Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 September 2026